TD Cowen reissued a hold rating on Crinetics Pharmaceuticals.
1 report, 1 independent
Updated Jul 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen reissued a hold rating on Crinetics Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TD Cowen
American investment bank
-
Crinetics Pharmaceuticals
company in San Diego, United States
Nothing else this week.
Related events
- TD Cowen upgraded Crescent Biopharma shares to 'strong-buy', while Wedbush reiterated 'outperform', and a CEO sold shares under a 10b5-1 plan.
- TD Cowen upgraded Cabaletta Bio shares to strong-buy, while Jefferies reissued a buy rating, and MarketBeat provided consensus data.
- TD Cowen issued a buy rating and price target for Evolv Technologies Holdings, Inc.
- TD Cowen maintained a Buy rating on Forgent on September 15, 2026.
- TD Cowen, Stephens, Citigroup, and MarketBeat provided new analyst ratings and coverage for Covenant Logistics Group, Inc.